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Summary
Background: The transferrin saturation (TSAT) ratio
is a commonly used indicator of iron deficiency and
iron overload in clinical practice but precise rela-
tionships with total and cardiovascular mortality
are unclear.
Purpose: To better understand this relationship, we
explored the association of TSAT ratio (serum iron/
total iron binding capacity) with mortality in the
general population.
Methods: The relationships of TSAT ratio with total
and cardiovascular mortality were explored in
15 823 subjects age 20 and older from the Third
National Health and Nutrition Examination Survey
(1988–94). All subjects had vital status assessed
through to 2006.
Results: During follow-up, 9.7% died of which 4.4%
were from cardiovascular disease. In unadjusted
analysis, increasing TSAT ratio was inversely asso-
ciated with mortality. With adjustment for baseline
demographic and clinical characteristics, the
TSAT–mortality relationship followed a j-shaped
pattern. Compared with the referent group [ratio
23.7–31.3%: hazard ratio (HR) =1.00], subjects in
the lowest two quartiles, <17.5 % and 17.5–23.7 %,
experienced significantly higher mortality risks of
1.45 (1.19–1.77) and 1.27 (1.06–1.53), respectively,
whereas subjects in the highest quartile, >31.3 %,
experienced significantly higher mortality risks of
1.23 (1.01–1.49). The pattern of association was
more pronounced for cardiovascular mortality with
significantly higher mortality risks for the lowest two
quartiles [HR=2.09 (1.43–3.05) and 1.90 (1.33–
2.72), respectively] and highest quartile HR=1.59
(1.05–2.40).
Conclusions: Both low and high TSAT ratios are sig-
nificantly and independently associated with
increased total and cardiovascular mortality. The
optimal TSAT ratio associated with the greatest sur-
vival is between 24% and 40%.
Introduction
Serum transferrin saturation (TSAT) ratio is a com-
monly used laboratory measure of iron deficiency
and iron overload in clinical practice.1,2 It has
become a first step in the routine screening of iron
deficiency anaemia in patients with chronic kidney
disease and for the detection of pathological iron
overload in assessment for hemochromatosis.3–6
Used alone or in combination with other measures
of iron metabolism, low levels of TSAT (typically
<20%) reflect a state of iron deficiency whereas
levels in excess of 50% indicate an excess of total
body iron. Despite its increasing use in clinical prac-
tice, few studies have addressed the association of
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TSAT with mortality in the general population.7,8
Such studies are important in determining the opti-
mal range for TSAT in clinical practice.
Two previous epidemiological studies have
examined the relationship of TSAT ratio with mor-
tality. An earlier report based on analysis of data
from the First National Health and Nutrition
Examination Survey (NHANES 1) Epidemiologic
Follow-up Study found a significant inverse
association of TSAT with overall and cardiovascular
mortality but only for white men and women.7
A more recent study by Mainous et al.8 demon-
strated elevated mortality risks for TSAT levels
>55%. These seemingly discordant findings leave
several unanswered questions as to the true associ-
ation between TSAT ratio and the risk of death.
On one hand, there is a strong biological argument
to suggest that iron deficiency may theoretically
increase mortality risk,1,9 whereas on the other
hand excess iron stores contribute to pathological
iron overload resulting in parenchymal liver
damage, cardiac abnormalities and diabetes
mellitus.10–13
The purpose of this study was to (i) re-examine the
nature of the relationship between TSAT ratio and
mortality in a nationally representative cohort of the
US population, (ii) identify threshold values for mor-
tality risks and (iii) explore interactions with other
disease states that may have significant clinical
implications.
Methods
The NHANES III was a national survey conducted
by the National Center for Health Statistics that as-
sessed the health status of a representative sample of
non-institutionalized persons living in the USA from
1988 to 1994.14,15 The NHANES III used a complex
stratified multistage sampling design with over-
sampled vulnerable groups including the elderly
and minority populations. The data collection instru-
ment consisted of a standardized questionnaire fol-
lowed by a detailed physical examination that
included collection of blood specimens. Almost all
NHANES participants were linked to records in the
National Death Index through 31 December
2006.15 Only 26 of the 20 024 eligible participants
(0.1%) did not have follow-up status. Ethical ap-
proval for the study was obtained from the Ethics
Review Board of the National Centre for Health
Statistics and further ethical approval for use of
NHANES data that is freely available on the web is
not required as it is anonymized.
Sample
The current analysis was restricted to adult NHANES
III participants, 20 years of age or older (N=17 030)
who had valid serum creatinine measurements
(N=15823). Serum creatinine values were used to
determine the estimated glomerular filtration rate
(eGFR) in ml/min per 1.73m2, for all participants.16
Baseline measurements
The NHANES III captured data on demographic fac-
tors, self-reported clinical conditions, lifestyle fac-
tors, socioeconomic indicators, physical attributes
and an extensive range of laboratory biomarkers.
Blood samples were obtained from non-fasting per-
sons and frozen serum sent to the Centers for
Disease Control and Prevention for analysis. Serum
iron and total iron binding capacity (TIBC) were
measured colorimetrically (Alpkem RFA analyzer,
Clackamas, OR), and 1% thiourea was added to
complex copper to prevent copper interference.17,18
TSAT saturation was computed from the serum iron
(Fe) divided by the TIBC. Serum ferritin was mea-
sured with the BioRad Quantimmune IRMA kit
(BioRad Laboratories, Hercules, CA). Haemoglobin
was measured using a Coulter S-Plus Jr electronic
counter (Coulter Electronics, Hialeah, FL). Serum
creatinine concentrations were measured by the
modified kinetic Jaffe reaction using a Hitachi 737
analyzer (Boehringer Mannheim Corp.,
Indianapolis, IN) and glomerular filtration rate was
estimated from the abbreviated Modification of Diet
in Renal Disease (MDRD) Study formula.19,20
Assessment of all-cause and cardiovascular
mortality
Deaths were analysed for all causes and cardiovas-
cular causes. Cardiovascular causes of death were
identified from the International Classification of
Diseases (ICD 10) diagnosis codes in the NHANES-
linked mortality files and included: deaths from acute
myocardial infarction (121–122), other acute ischae-
mic heart disease (124), atherosclerotic cardiovascu-
lar disease (125.0), all other forms of chronic
ischaemic heart disease (120, 125.1, 125.9) and cere-
brovascular disease (160–169).
Statistical analysis
All subjects were stratified into quartiles of TSAT ratio
and characteristics were compared across quartile
groups. For continuous variables, differences across
quartiles were tested with analysis of variance. For
dichotomous variables, comparisons across quartiles
were conducted using the chi-square.
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For the principal analyses, years of follow-up for
each individual were calculated from baseline to the
date of death for decedents and to 31 December
2000 for those still alive. To assess the mortality
impact of TSAT levels over longer periods, follow-
up was extended to 31 December 2006. Total and
cardiovascular mortality rates were calculated for
the entire cohort and quartile groups expressed as
deaths per 1000 person-years. Cox proportional
hazard regression models examined the relation-
ships of TSAT ratio to all-cause and cardiovascular
mortality adjusting for baseline characteristics with
the third quartile was set as the referent. Adjustments
were made for baseline comorbid conditions, life-
style factors, nutritional and socioeconomic indica-
tors. The poverty income ratio (PIR) was used as an
indicator of socioeconomic status and represents the
annual family income divided by the federal poverty
line. This line is adjusted each calendar year for in-
flation and varies with the size of the household. To
determine whether the presence of anaemia, im-
paired kidney function or inflammation altered the
relationship between TSAT and mortality, we cre-
ated a number of interaction terms in the Cox
model to test for effect modification. For each cov-
ariate, the unadjusted hazard ratio (HR) of death and
adjusted HR of death were calculated with corres-
ponding 95% confidence intervals. Weighted multi-
variable Cox regression was used to account for the
complex survey design, the unequal probability of
subject selection and non-response rates. Model fit
was assessed using the Taylor method and 2 log
likelihood ratio (SAS-callable SUDAAN statistical
software from Research Triangle Institute).
Sensitivity analyses
Sensitivity analyses were conducted to explore the
robustness of our observations. First, we determined
whether the pattern of association between TSAT
and mortality was consistent across multiple high-
risk groups. Second, we re-classified the study popu-
lation according to deciles of TSAT. With this clas-
sification, we were able to identify with greater
precision threshold values above or below which
mortality risks varied. Third, we evaluated whether
the mortality impact of high and low TSAT values
varied over time by evaluating risks in the first
5 years of follow-up (early impact).
Results
Baseline characteristics of the population
The mean characteristics of all study participants age
20 and over are shown in Table 1. The weighted
mean age of subjects was 44.7 years (0.5), 77%
were White, 10.4% were Black and 5.1% were
Mexican-American. The mean values for TSAT (SE
%) were 26.3 (0.22)%; haemoglobin 14.2 g/dl
(0.03) and serum ferritin level 129 (2.0) ng/ml.
Characteristics of population by quartile of
serum transferrin
The mean TSAT ratio increased from 12.9% to
40.6% from the lowest to the highest quartile
group. In general, lower quartiles were associated
with an increasing prevalence of cardiovascular
and non-cardiovascular conditions.
All-cause mortality
During 8.7 years of follow-up (9.1 years, survivors;
5.2 years, decedents), 2506 (9.7%) in the study
group died. Of the total deaths, 1182 (47.2%)
were ascribed to cardiovascular disease. The crude
all-cause mortality rate decreased significantly from
13.3 per 1000 person-years to 9.1 per 1000 person-
years with increasing quartile of TSAT (Table 2).
The corresponding unadjusted HRs were 1.40
(1.15–1.71) and 1.39 (1.17–1.65) in the lowest two
quartiles to 0.95 (0.79–1.14) in the highest quartile
compared with the referent group (Q3,
23.7–31.3%). With adjustment for age only, the pat-
tern of association between TSAT and mortality fol-
lowed a j-shaped curve. Compared with the referent
(23.7–31.3%, HR=1.00), participants in the lowest
two quartiles experienced significantly higher mor-
tality risks, HR=1.52 (1.28–1.81) and HR=1.27
(1.09–1.49) whereas those in the highest quartile
HR=1.17 (0.97–1.40) also tended to have higher
mortality risk. With adjustment for demographic
and clinical variables, the pattern of association
was more pronounced and when we adjusted add-
itionally for haemoglobin and serum ferritin the pat-
tern was accentuated even further with significantly
higher mortality for subjects in the highest quartile
group (HR=1.23, 1.01–1.49).
Stratification by disease group
The stratified analysis explored the association of
TSAT and mortality across age, race and gender
groups as well as across disease categories
(Table 3). There were significant age–gender inter-
actions as illustrated in Figure 1a and b (P<0.05).
For men, the j-shaped association of TSAT with mor-
tality was present only for older age (>65 years) sub-
jects as illustrated in Figure 1a. For women, the
opposite was true, with the j-shaped mortality pat-
tern seen only in subjects’ age <45 years and to a
lesser degree in subjects age 45–65 years as shown
TSAT ratio and mortality 625
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Table 1 Characteristics of study participants by quartiles of TSAT ratio
Patient characteristicsa Entire cohort TSAT Ratio % (quartiles)
First Second Third Fourth
(<17.5) (17.5–23.7) (23.7–31.3) (>31.3)
Demographics
Age at interview (years) 44.69 (0.45) 44.92 (0.48) 46.95 (0.58) 44.99 (0.59) 42.33 (0.56)
Gender
% Men 47.92 (0.42) 28.80 (1.21) 43.85 (1.07) 53.29 (0.99) 61.15 (0.92)
% Women 52.08 (0.42) 71.20 (1.21) 56.15 (1.07) 46.71 (0.99) 38.85 (0.92)
Race/ethnicity
%White-non Hispanic 76.97 (1.21) 72.63 (1.66) 76.32 (1.53) 78.36 (1.41) 79.58 (1.40)
% Black non-Hispanic 10.35 (0.60) 13.70 (0.99) 11.40 (0.78) 9.42 (0.69) 7.74 (0.51)
% Mexican American 5.10 (0.41) 5.76 (0.58) 5.06 (0.49) 4.78 (0.39) 4.92 (0.42)
% Other 7.58 (0.77) 7.90 (1.11) 7.23 (0.99) 7.44 (0.93) 7.77 (1.05)
Clinical condition (%)
Coronary artery disease 6.00 (0.33) 6.27 (0.53) 7.36 (0.65) 5.86 (0.54) 4.77 (0.58)
History of myocardial infarction 3.49 (0.26) 3.61 (0.39) 4.56 (0.59) 3.16 (0.44) 2.78 (0.30)
Angina by Rose questionnaire 4.36 (0.33) 4.61 (0.48) 5.47 (0.72) 4.52 (0.44) 3.14 (0.61)
Chronic bronchitis 6.34 (0.27) 6.38 (0.52) 7.56 (0.62) 5.91 (0.57) 5.67 (0.52)
Gout 2.73 (0.20) 2.89 (0.34) 2.99 (0.47) 2.94 (0.42) 2.20 (0.26)
Congestive heart failure 2.19 (0.16) 2.67 (0.34) 2.80 (0.38) 1.97 (0.30) 1.51 (0.24)
Stroke 2.01 (0.17) 2.46 (0.35) 2.50 (0.31) 1.75 (0.26) 1.49 (0.25)
Arthritis 18.55 (0.60) 20.93 (1.05) 21.66 (0.97) 18.23 (0.90) 14.41 (1.03)
Diabetes (by history) 5.02 (0.26) 5.72 (0.46) 6.18 (0.46) 4.78 (0.41) 3.73 (0.42)
Hypertension (by history) 23.74 (0.67) 27.18 (1.39) 27.78 (1.11) 22.81 (0.91) 18.56 (0.89)
JNC VII staging of hypertensionb
Normal < 120/80 76.10 (0.62) 76.69 (1.24) 74.30 (0.84) 75.19 (0.88) 77.98 (1.06)
Pre-hypertension 120/80 20.07 (0.55) 19.60 (1.13) 20.18 (0.75) 21.71 (0.84) 18.82 (1.03)
Stage I 140/90 3.36 (0.21) 3.15 (0.40) 4.87 (0.55) 2.59 (0.34) 2.97 (0.34)
Stage II 160/100 0.47 (0.07) 0.56 (0.15) 0.65 (0.16) 0.50 (0.12) 0.23 (0.06)
Family history of MI < 50 yearsb 17.10 (0.51) 17.43 (1.08) 18.55 (0.93) 16.50 (0.97) 16.19 (0.97)
Lifestyle and socioeconomic indicators (%)
Tobacco use
Current smokers 28.40 (0.85) 27.79 (1.49) 26.72 (1.27) 25.17 (1.24) 33.28 (1.32)
Former smokers 25.94 (0.61) 23.52 (1.24) 26.92 (1.13) 28.22 (1.16) 24.89 (0.93)
Never smokers 45.65 (0.79) 48.69 (1.36) 46.36 (1.12) 46.61 (1.70) 41.83 (1.50)
Physically inactive 15.06 (0.77) 18.41 (1.16) 15.66 (1.03) 13.49 (1.23) 13.40 (1.01)
Body mass index (kg/m2) 26.5 (0.11) 27.5 (0.23) 27.2 (0.17) 26.5 (0.15) 25.3 (0.13)
Poverty income ratio (PIR)c 0.90 (0.02) 0.79 (0.03) 0.89 (0.03) 0.92 (0.03) 0.96 (0.03)
Specific haematology variables
Serum TSAT (%) 26.29 (0.22) 12.85 (0.11) 20.62 (0.05) 27.25 (0.05) 40.57 (0.23)
Haemoglobin (g/dl) 14.15 (0.03) 13.41 (0.05) 14.06 (0.05) 14.31 (0.05) 14.66 (0.03)
Anaemia males (%) 3.46 (0.28) 8.32 (0.81) 5.00 (0.81) 2.34 (0.43) 1.65 (0.27)
Anaemia females (%) 10.73 (0.73) 20.86 (1.29) 7.01 (0.82) 6.80 (0.78) 5.28 (0.92)
Serum ferritin (ng/ml) 128.97 (2.02) 86.59 (2.44) 121.36 (3.10) 136.41 (3.69) 161.30 (4.45)
Serum ferritin < 12 ng/ml (%) 4.80 (0.25) 15.77 (0.94) 2.12 (0.35) 1.73 (0.32) 1.37 (0.36)
Other laboratory variables
Serum albumin (g/dl) 4.18 (0.02) 4.07 (0.02) 4.18 (0.02) 4.21 (0.02) 4.24 (0.03)
Serum creatinine (mg/dl) 1.07 (0.00) 1.04 (0.01) 1.09 (0.01) 1.08 (0.00) 1.08 (0.00)
GFR MDRD (ml/min/1.73m2)d 99.62 (0.56) 100.28 (0.63) 96.90 (0.83) 99.55 (0.70) 101.45 (0.62)
aValues are reported as % or mean with standard errors (SE). bThe Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. cThis is a calculated variable based on family
income and family size using tables published each year by the Bureau of the Census in a series ‘Current Population Reports’
on poverty in the USA. dGlomerular filtration rate (ml/min per 1.73m2) was based on the MDRD Study equation (20).
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in Figure 1b. The association of TSAT with mortality
varied by race with the j-shaped mortality pattern
observed in Whites and Blacks but not in
Mexican-Americans. The j-shaped pattern of associ-
ation of TSAT with mortality was generally consist-
ent across most represented categories with the
exception of subjects with coronary disease or a
haemoglobin <11.5 g/dl, where mortality risks did
not increase for the highest transferrin quartile.
Cardiovascular mortality
Cardiovascular mortality rates decreased signifi-
cantly from 6.45 to 4.04 per 1000 person-years
with increasing quartile of TSAT (Table 4). Without
adjustment, the mortality risks for subjects in the
lowest two quartiles were significantly higher than
the referent group (HR=1.74 (1.46–2.08) and
HR=1.72 (1.36–2.17), respectively] and the mortal-
ity risks for those in the highest quartile tended also
to be higher, although non-significant. With adjust-
ment for baseline differences in comorbid condi-
tions and serum albumin, the mortality risks
remained significantly higher for subjects in the
lowest quartiles, but became significant for subjects
in the highest quartile (HR=1.53, 1.03–2.26) com-
pared with the referent. Additional adjustment for
haemoglobin and serum ferritin accentuated this
relationship and the pattern of association was
similar for most subgroups as demonstrated in
Table 4.
Sensitivity analysis
When the study population was reclassified accord-
ing to deciles of TSAT, subjects in the lowest five
deciles as well as those in the highest decile
(TSAT>39.7%) experienced significantly higher
mortality risks than that of the referent group (sub-
jects in the sixth decile; TSAT ratio 23.7–26.4%), as
shown in Figure 2. Furthermore, the pattern of asso-
ciation between TSAT and mortality at 5 years (early
impact analysis) of follow-up was virtually identical
to those of the original analyses (Supplementary
Table 1).
Discussion
In this population-based cohort, we demonstrated a
significant and independent relationship between
TSAT with total and cardiovascular mortality. The
pattern of association was j-shaped with signifi-
cantly higher mortality for subjects with TSAT
values <23.7% and higher than 31.3%. The associ-
ation of TSAT with mortality differed by race and
sex. Among Whites and Blacks, low and high
Table 2 Relationship between TSAT ratio (%) and all-cause mortality in the US population
TSAT Ratio (%) Quartiles
First Second Third Fourth
(<17.5) (17.5–23.7) (23.7–31.3) (>31.3)
(N=3905) (N=3933) (N=3936) (N=3924)
All participants
Total alive (N, %) 13 192 3241 (88.64) 3235 (88.53) 3357 (91.65) 3359 (91.94)
Total deaths (N, %) 2506 664 (11.36) 698 (11.47) 579 (8.35) 565 (8.06)
Person-years at risk 308 831767 338966 626 379433911 414 233020
Unadjusted death rate per 1000 person-years 13.34 13.25 9.56 9.11
Age-adjusted death rate per 1000 person-years 11.41 10.09 8.14 9.33
HR for deatha Referent group
Unadjusted 1.40 (1.15–1.71) 1.39 (1.17–1.65) 1.00 0.95 (0.79–1.14)
Adjusted for age 1.52 (1.28–1.81) 1.27 (1.09–1.49) 1.00 1.17 (0.97–1.40)
Adjusted demographics only 1.63 (1.38–1.94) 1.32 (1.12–1.56) 1.00 1.14 (0.95–1.37)
Plus comorbid conditions and serum albumin 1.53 (1.25–1.86) 1.30 (1.08–1.56) 1.00 1.20 (0.99–1.44)
Plus haemoglobin 1.41 (1.16–1.72) 1.26 (1.05–1.52) 1.00 1.25 (1.03–1.51)
Plus serum ferritin 1.45 (1.19–1.77) 1.27 (1.06–1.53) 1.00 1.23 (1.01–1.49)
Plus poverty income ratiob 1.43 (1.14–1.80) 1.28 (1.07–1.54) 1.00 1.21 (1.00–1.48)
aHRs and 95% confidence intervals. Multivariate models sequentially adjusted for demographic characteristics, comorbid
conditions, laboratory variables and socioeconomic indicators. There were missing data on 125 subjects leaving 15, 698 for
the multivariable analysis. bPoverty income ratio: this is a calculated variable based on family income and family size using
tables published each year by the Bureau of the Census in a series ‘Current Population Reports’ on poverty in the USA.
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TSAT levels were associated with higher mortality
risk whereas no association was manifested in
Mexican-Americans. For men, the impact on mor-
tality was demonstrated only in older males,
whereas for women the j-shaped mortality associ-
ation was confined to younger females. The patterns
of association between TSAT and cardiovascular
mortality were similar in direction although greater
in magnitude and strength. Our findings demon-
strate that the TSAT saturation is a useful prognostic
tool in clinical medicine and that low levels and
very high levels are independent markers of ele-
vated mortality risk. We suggest that the optimal
TSAT range for patient survival should be between
23% and 40% and that careful clinical assessment is
warranted for patients with low and high levels in
order to identify states of iron deficiency or iron
excess.
Our findings illustrate that very low levels of
TSAT, a marker of iron deficiency, and very high
levels of TSAT, a maker of iron overload, contribute
to increased all-cause and cardiovascular mortality.
Subjects with the lowest TSAT levels experienced
the highest mortality across most age, race and dis-
ease categories. We had speculated that the greater
burden of illness in these subjects could explain the
higher mortality risks; however, when we accounted
for these differences, the relationships between low
Table 3 Relationship between TSAT (%) and all-cause mortality in sub-populations of interesta
TSAT Ratio (%) Quartiles
First Second Third Fourth
(<17.5) (17.5–23.7) (23.7–31.3) (>31.3)
Subject groups Subjects (N)
By age Referent group
<45 years 7991 1.35 (0.74–2.47) 1.09 (0.61–1.95) 1.00 1.24 (0.67–2.29)
45–65 years 3896 1.62 (1.02–2.60) 1.18 (0.79–1.76) 1.00 0.97 (0.65–1.44)
>65 years 3811 1.55 (1.35–1.85) 1.24 (1.01–1.52) 1.00 1.12 (0.94–1.32)
By sex
Males 7347 1.52 (1.19–1.94) 1.42 (1.11–1.80) 1.00 1.37 (1.12–1.68)
Females 8351 1.33 (0.98–1.80) 1.12 (0.86–1.46) 1.00 1.05 (0.76–1.45)
By race
White 6644 1.56 (1.27–1.92) 1.30 (1.06–1.61) 1.00 1.11 (0.91–1.34)
Black 4177 1.70 (1.33–2.18) 1.20 (0.96–1.51) 1.00 1.27 (0.91–1.79)
Mexican 4258 1.13 (0.77–1.65) 1.12 (0.68–1.64) 1.00 0.87 (0.55–1.37)
By haemoglobin (g/dl)
<11.5 796 1.59 (0.80–3.14) 1.47 (0.81–2.65) 1.00 0.86 (0.33–2.24)
11.5–12.5 1708 1.51 (0.93–2.45) 0.99 (0.62–1.56) 1.00 1.48 (0.82–2.69)
>12.5/dl 12 963 1.44 (1.19–1.74) 1.24 (1.03–1.50) 1.00 1.17 (0.95–1.45)
By level of GFRb
<60 1002 2.10 (1.36–3.23) 1.80 (1.23–2.61) 1.00 1.15 (0.73–1.81)
60–89 4284 1.29 (1.00–1.66) 1.07 (0.81–1.42) 1.00 1.14 (0.84–1.53)
>90 10 412 1.42 (1.05–1.93) 1.25 (0.93–1.67) 1.00 1.38 (0.98–1.95)
By hypertension history
Hypertension present 4353 1.55 (1.22–1.96) 1.21 (0.94–1.55) 1.00 1.19 (0.86–1.66)
Hypertension absent 11 216 1.32 (0.99–1.77) 1.26 (0.99–1.61) 1.00 1.23 (0.99–1.53)
By coronary disease
Coronary disease present 742 1.47 (0.82–2.65) 1.22 (0.77–1.93) 1.00 0.92 (0.61–1.41)
Coronary disease absent 14 760 1.41 (1.15–1.71) 1.20 (0.98–1.47) 1.00 1.22 (0.98–1.52)
By heart failure
Heart failure present 595 1.80 (1.12–2.90) 1.73 (1.09–2.75) 1.00 1.20 (0.71–2.02)
Heart failure absent 15 080 1.38 (1.15–1.64) 1.17 (0.96–1.41) 1.00 1.17 (0.97–1.42)
aRelationships are expressed as HRs and 95% confidence intervals. bGlomerular filtration rate (ml/min per 1.73m2) was
based on the abbreviated MDRD Study equation.
628 A.G. Stack et al.
by guest on August 10, 2015
D
ow
nloaded from
 
TSAT levels and mortality remained significant. To
exclude the possibility that our findings were due to
low haemoglobin levels, poor nutrition and low
socioeconomic status, we accounted for these
potential confounders in multivariable models and
our results remained steadfast. Indeed when we ad-
justed for baseline differences in haemoglobin and
serum ferritin, the associations between TSAT and
mortality become even stronger. Our results also
demonstrate that elevated TSAT levels predict all-
cause mortality in the general population. Unlike
Sempos et al.,7 we found that TSAT>39.7% was
significantly associated with increased mortality.
Our findings extend the observations of Mainous
et al.8 in several ways. First, we provide greater spe-
cification of the gradient of risk across a wide range
of serum TSAT. Second, we demonstrate that the
upper threshold values for elevated mortality are ap-
preciably lower than previously reported (40% vs.
55%).8
This study also provides important new insights
into relationships between TSAT ratio and mortality
among men and women. For men, the j-shaped
mortality association was only observed among
Figure 1. Association of TSAT ratio (%) in quartile groups with all-cause mortality in (a) men and (b) women. In (a),
*P<0.05, **P<0.01 vs. referent quartile 23.7–31.3% (N=7405); in (b), *P<0.05 vs. referent quartile 23.7–31.3%
(N=8418). Adjusted for race, comorbid conditions, serum albumin, ferritin, haemoglobin level and poverty income ratio.
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those >65 years with no significant relationship for
those <65 years. In contrast, for women, the j-
shaped TSAT–mortality pattern was only observed
for those age <45 years. We had speculated that a
higher prevalence of anaemia in younger females
might in part be responsible for the surprisingly
elevated mortality risk. However, adjusting for
haemoglobin levels and serum ferritin did not ma-
terially alter this risk. Similarly, the association be-
tween TSAT levels and mortality was confined to
men >65 years and did not attenuate following
adjustment for haemoglobin, nutritional or
Table 4 Relationship between TSAT (%) and cardiovascular mortality in the US population
First Second Third Fourth
(<17.5) (17.5–23.7) (23.7–31.3) (>31.3)
(N=3905) (N=3933) (N=3936) (N=3924)
All participants Subjects (N)
Cardiovascular deaths (N) 1182 341 (5.49) 338 (5.55) 245 (3.26) 258 (3.57)
Non-cardiovascular deaths (N) 1324 323 (5.86) 360 (5.92) 334 (5.09) 307 (4.49)
Person-years 308 831767 338966 626 379433 911 414233020
Cardiovascular death rate per
1000 person-years
6.45 6.41 3.73 4.04
Age-adjusted cardiovascular death
rate per 1000 person-years
5.54 4.80 3.17 4.21
Relative risk death
Unadjusted 1.74 (1.46–2.08) 1.72 (1.36–2.17) 1.00 1.08 (0.83–1.40)
Adjusted for demographic factors
(age, sex and race)
2.10 (1.79–2.46) 1.66 (1.31–2.10) 1.00 1.30 (0.99–1.70)
Plus comorbid conditions
and serum albumin
2.10 (1.44–3.04) 1.88 (1.34–2.65) 1.00 1.53 (1.03–2.26)
Plus haemoglobin 1.94 (1.33–2.81) 1.82 (1.28–2.57) 1.00 1.58 (1.06–2.35)
Plus ferritin 2.09 (1.43–3.05) 1.90 (1.33–2.72) 1.00 1.59 (1.05–2.40)
Plus poverty income ratioa 2.01 (1.58–2.54) 1.60 (1.19–2.16) 1.00 1.31 (0.99–1.77)
Stratified analysis
By age (years)
<65 11 653 2.52 (0.88–7.24) 1.52 (0.56–4.16) 1.00 1.45 (0.68–3.08)
565 4045 2.30 (1.69–3.11) 2.07 (1.45–2.95) 1.00 1.59 (103–2.47)
By sex
Males 7347 2.34 (1.35–4.06) 1.85 (1.11–3.07) 1.00 1.61 (1.07–2.44)
Females 8351 1.88 (1.19–2.96) 1.82 (1.11–2.98) 1.00 1.50 (0.79–2.86)
By haemoglobin (g/dl)
<11.5 796 2.62 (0.82–8.38) 3.32 (0.97–11.35) 1.00 0.74 (0.08–6.50)
11.5–12.5 1708 3.21 (1.10–9.31) 1.24 (0.48–3.18) 1.00 3.86 (1.42–10.47)
>12.5 12 963 2.01 (1.39–2.91) 1.79 (1.28–2.50) 1.00 1.40 (0.94–2.10)
By level of GFRb
<60 1002 2.27 (1.20–4.32) 2.47 (1.16–5.22) 1.00 0.93 (0.37–2.31)
60–90 4284 2.13 (1.15–3.94) 2.20 (1.38–3.50) 1.00 2.18 (1.22–3.88)
>90 10 412 1.97 (1.04–3.76) 1.03 (0.56–1.88) 1.00 1.31 (0.65–2.66)
By hypertension history
Hypertension present 4353 2.16 (1.39–3.37) 1.48 (0.93–2.35) 1.00 0.99 (0.61–1.61)
Hypertension absent 11 216 1.90 (1.29–2.81) 1.99 (1.31–3.04) 1.00 1.98 (1.27–3.08)
By coronary disease
Coronary disease present 742 4.41 (1.69–11.56) 3.62 (1.61–8.13) 1.00 2.41 (0.99–5.83)
Coronary disease absent 14 760 1.81 (1.32–2.46) 1.56 (1.15–2.13) 1.00 1.38 (0.97–1.96)
By heart failure
Heart failure present 595 1.40 (0.64–3.06) 1.74 (0.72–4.21) 1.00 1.41 (0.58–3.42)
Heart failure absent 15 080 2.15 (1.52–3.04) 1.74 (1.27–2.37) 1.00 1.48 (1.01–2.17)
aGlomerular filtration rate (ml/min per 1.73m2) was based on the abbreviated MDRD Study equation. bPoverty income ratio:
this is a calculated variable based on family income and family size using tables published each year by the Bureau of the
Census in a series ‘Current Population Reports’ on poverty in the USA.
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socioeconomic markers. It is quite possible that the
TSAT ratio is a strong indicator of iron deficient
states and/or iron overload states in these patient
subgroups and therefore the ratio has the strongest
association with mortality in these subgroups.
An important aspect of this study was the explor-
ation of potential interactions of TSAT with mortality
in patients with and without chronic disease. In gen-
eral, we found that the pattern of association of
TSAT with mortality was generally consistent
across most disease groups with some exceptions.
In particular, the j-shaped mortality relationship was
more pronounced and significant among subjects
with heart failure and hypertension. The signifi-
cantly higher mortality for subjects with low TSAT
and heart failure would support the rationale for cor-
rection of iron deficient states in this category of
disease. However, the higher than expected mortal-
ity for TSAT levels >39.7%, although not significant,
should merit caution. We did not find evidence that
the relationship between transferrin and mortality
differed by level of kidney function either for all-
cause mortality or cardiovascular mortality, al-
though the magnitude of the HRs for low transferrin
levels was greater for subjects with eGFR<60ml/
min than above. This would suggest that iron defi-
ciency is an equally important predictor of mortality
across all categories of kidney impairment.
There are several possible pathological mechan-
isms that might explain the j-shaped association of
TSAT with mortality.9–13,21 The development of iron
deficiency anaemia as a consequence of iron defi-
ciency is a very plausible pathway; however, the
adjustment for haemoglobin in the analysis suggests
that other mechanisms are important. Adequate iron
stores are also necessary for several non-erythropoi-
esis biologic processes such as preservation of
immune function, thermoregulation and cogni-
tion.1,9 Moreover, chronic iron deficiency has
been reported to cause structural alterations in car-
diomyocytes and impair cardiac performance, es-
tablishing a theoretical link with increased
cardiovascular mortality.21 At the other end of the
spectrum, there is evidence to suggest that excess
iron stores may confer increased mortality risk
through accumulation of iron in several vital
organs such as the heart, liver and pancreas.10–13
Equally important are the observations that large
doses of parenteral iron used in the treatment of
iron deficient states contribute to oxidative stress
and increased susceptibility to infection.22–25
Although the precise mechanisms of elevated mor-
tality are unknown, there are compelling biologic
arguments to support associations between patho-
logical states of iron deficiency and iron overload.
This study has some limitations including, loss to
follow-up although minimal, lack of information on
other potentially important explanatory variables,
errors in measurement of baseline variables and mis-
classification of cardiovascular causes of death.
Nevertheless, this study has several strengths
which enhance its internal and external validity;
Figure 2. Association of TSAT ratio (%) in decile groups with all-cause mortality. *P<0.05, **P<0.01 vs. referent quartile
23.7–31.3%. Multivariable model adjusted for age, sex, race, comorbid conditions, serum albumin, ferritin, haemoglobin
level and poverty income ratio.
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the sample large size and the ability to test the hy-
pothesis in several interest groups; the standardized
methods of data collection; the relatively long
follow-up, the large number of events; the outcome
of mortality as the end point; and the ability to adjust
sequentially for a large number of known mortality
predictors that were captured in the baseline
questionnaire.
In conclusion, this study demonstrates a strong
independent j-shaped association of TSAT with all-
cause and cardiovascular mortality. This association
was present for older men and younger women, for
Black and White populations but not Mexican
Americans; and remained strong regardless of
comorbid conditions, nutritional markers and socio-
economic indicators. Threshold analyses found that
the optimal cut-points for TSAT, at which the lowest
mortality was observed, were between 23% and
40%, above and below which mortality risks were
significantly increased. Our results suggest that the
optimal target range for TSAT should be between
24% and 40% and provide support for the correc-
tion of low TSAT levels in the general population
while at the same time advising caution against ex-
cessive iron loading to levels beyond 40%.
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